HK1127280A1 - Dividable galenical form allowing modified release of the active ingredient - Google Patents

Dividable galenical form allowing modified release of the active ingredient

Info

Publication number
HK1127280A1
HK1127280A1 HK09104299.1A HK09104299A HK1127280A1 HK 1127280 A1 HK1127280 A1 HK 1127280A1 HK 09104299 A HK09104299 A HK 09104299A HK 1127280 A1 HK1127280 A1 HK 1127280A1
Authority
HK
Hong Kong
Prior art keywords
active ingredient
modified release
tablet
form allowing
galenical form
Prior art date
Application number
HK09104299.1A
Other languages
English (en)
Inventor
Gilles Fonknechten
Patrick Genty
Jean-Manuel Pean
Patrick Wuthrich
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39796790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1127280(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of HK1127280A1 publication Critical patent/HK1127280A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Chemistry (AREA)
HK09104299.1A 2008-03-21 2009-05-11 Dividable galenical form allowing modified release of the active ingredient HK1127280A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801561A FR2928836B1 (fr) 2008-03-21 2008-03-21 Forme galenique secable permettant une liberation modifiee du principe actif

Publications (1)

Publication Number Publication Date
HK1127280A1 true HK1127280A1 (en) 2009-09-25

Family

ID=39796790

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09104299.1A HK1127280A1 (en) 2008-03-21 2009-05-11 Dividable galenical form allowing modified release of the active ingredient

Country Status (37)

Country Link
US (3) US20090238870A1 (zh)
EP (2) EP2103302A1 (zh)
JP (2) JP5231906B2 (zh)
KR (3) KR20090101048A (zh)
CN (1) CN101347414B (zh)
AP (1) AP2729A (zh)
AR (1) AR067993A1 (zh)
AU (1) AU2008207680B8 (zh)
BR (1) BRPI0803631A2 (zh)
CA (1) CA2629670C (zh)
CL (1) CL2008002486A1 (zh)
CO (1) CO6020017A1 (zh)
CR (2) CR10317A (zh)
CU (1) CU23970B1 (zh)
EA (1) EA200801862A1 (zh)
EC (1) ECSP088727A (zh)
FR (1) FR2928836B1 (zh)
GT (1) GT200800163A (zh)
HK (1) HK1127280A1 (zh)
HN (1) HN2008001466A (zh)
IL (1) IL193611A0 (zh)
JO (1) JO3052B1 (zh)
MA (1) MA31218B1 (zh)
ME (1) ME01031B (zh)
MX (1) MX2008011579A (zh)
MY (1) MY150660A (zh)
NI (1) NI200800256A (zh)
NZ (1) NZ570715A (zh)
PE (1) PE20090991A1 (zh)
SA (1) SA08290555B1 (zh)
SG (1) SG155819A1 (zh)
SV (1) SV2008003023A (zh)
TW (1) TWI396561B (zh)
UA (1) UA86731C2 (zh)
UY (1) UY31307A1 (zh)
WO (1) WO2009125087A1 (zh)
ZA (1) ZA200807354B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615860B8 (pt) 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN106892856A (zh) * 2017-02-06 2017-06-27 山东科源制药股份有限公司 一种格列齐特粗品重结晶的制备方法
MX2022011505A (es) 2020-03-16 2022-10-07 Gruenenthal Gmbh Comprimido ranurado.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH069375A (ja) * 1992-04-10 1994-01-18 Takeda Chem Ind Ltd 分割可能な連結錠剤
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
CA2320900C (en) * 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
ES2302364T3 (es) * 1998-04-03 2008-07-01 Kyowa Hakko Kogyo Co., Ltd. Tableta divisible y paquete perforado por presion.
JP2006052230A (ja) * 1998-04-03 2006-02-23 Kyowa Hakko Kogyo Co Ltd 分割錠剤及びプレススルーパック
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
US6667060B1 (en) * 1999-03-31 2003-12-23 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
DE10117208A1 (de) * 2001-04-06 2002-10-10 Wolff Walsrode Ag Verfahren zur Herstellung von niederviskosen, wässrigen Celluloseetherlösungen
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
EP1741435A4 (en) * 2004-04-29 2009-11-11 Lotus Pharmaceutical Co Ltd ORAL VAPORS WITH MODIFIED RELEASE AND METHOD OF MANUFACTURING THEM
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
EP1827453A1 (en) * 2004-12-06 2007-09-05 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
EP1868587A2 (en) * 2005-04-08 2007-12-26 Abbott Laboratories Pharmaceutical formulations comprising fenofibric acid and/or its salts
JP5046501B2 (ja) * 2005-08-18 2012-10-10 帝人ファーマ株式会社 複数の薬物を分離して保持する錠剤
US9028867B2 (en) * 2005-08-18 2015-05-12 Teijin Pharma Limited Formulation having accurate dose-dividing function
BRPI0615860B8 (pt) * 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
JP5361188B2 (ja) * 2006-08-10 2013-12-04 武田薬品工業株式会社 医薬組成物
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤

Also Published As

Publication number Publication date
AR067993A1 (es) 2009-10-28
AU2008207680A1 (en) 2009-10-08
FR2928836A1 (fr) 2009-09-25
AP2729A (en) 2013-08-31
SG155819A1 (en) 2009-10-29
CO6020017A1 (es) 2009-03-31
CN101347414A (zh) 2009-01-21
AP2008004614A0 (en) 2008-10-31
IL193611A0 (en) 2009-08-03
US20140221449A1 (en) 2014-08-07
CR10317A (es) 2008-11-26
ZA200807354B (en) 2008-11-26
EP2103302A1 (fr) 2009-09-23
KR20110112266A (ko) 2011-10-12
CN101347414B (zh) 2011-11-23
SA08290555B1 (ar) 2011-07-20
KR101693189B1 (ko) 2017-01-05
EA200801862A1 (ru) 2009-10-30
BRPI0803631A2 (pt) 2011-03-29
JP2009227651A (ja) 2009-10-08
AU2008207680B8 (en) 2010-05-13
ME01031B (me) 2012-10-20
CA2629670C (fr) 2012-04-17
KR20150035829A (ko) 2015-04-07
JO3052B1 (ar) 2017-03-15
MX2008011579A (es) 2009-09-21
US20130295176A1 (en) 2013-11-07
US20090238870A1 (en) 2009-09-24
FR2928836B1 (fr) 2011-08-26
MY150660A (en) 2014-02-14
NZ570715A (en) 2010-10-29
TWI396561B (zh) 2013-05-21
MA31218B1 (fr) 2010-03-01
GT200800163A (es) 2010-05-21
CA2629670A1 (fr) 2008-10-01
CU20080179A7 (es) 2011-04-26
JP2010209103A (ja) 2010-09-24
EP3025706A1 (fr) 2016-06-01
CL2008002486A1 (es) 2008-12-26
ECSP088727A (es) 2008-10-31
CU23970B1 (es) 2013-12-27
KR20090101048A (ko) 2009-09-24
HN2008001466A (es) 2011-04-25
JP5231906B2 (ja) 2013-07-10
PE20090991A1 (es) 2009-07-18
NI200800256A (es) 2010-02-11
TW200940109A (en) 2009-10-01
WO2009125087A1 (fr) 2009-10-15
AU2008207680B2 (en) 2010-04-22
UA86731C2 (ru) 2009-05-12
CR20140334A (es) 2014-08-20
SV2008003023A (es) 2010-07-29
UY31307A1 (es) 2008-10-31

Similar Documents

Publication Publication Date Title
HK1127280A1 (en) Dividable galenical form allowing modified release of the active ingredient
HRP20191005T1 (hr) Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak
WO2008057266A3 (en) Dry granulation binders, products, and use thereof
HK1128587A1 (en) Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
IL209054A (en) A method of producing 2992 bibw compressed intermediate, this compressed intermediate and solid pharmaceutical compositions containing this compressed intermediate
CL2015000893A1 (es) Formulación de una forma farmacéutica sólida de desintegración rápida que comprende carbonato de calcio funcionalizado, un ingrediente activo y por lo menos un desintegrante; y método para su fabricación.
MX2015017036A (es) Metodo para producir celulas progenitoras renales y farmaco que comprende las mismas.
WO2009058798A3 (en) Orally disintegrated dosage form
TN2012000279A1 (en) Processes for the manufacture of a pharmaceutically active agent
IL213620A0 (en) Preparation and therapeutic applications of (2s, 3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl]-3,5-difluorobenzamide
UA108528C2 (uk) Стос множини целюлозовмісних абсорбуючих рушників і спосіб виготовлення стосу
BRPI0905790A2 (pt) 'micropartícula, método para a fabricação de micropartícula e preparação farmacêutica
NI201100227A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica.
NZ603199A (en) Orally disintegrating tablet containing acarbose
PL1994926T3 (pl) Preparaty walsartanu
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2011018185A3 (en) Pharmaceutical tablet comprising rosuvastatin calcium
CL2007003006A1 (es) Forma cristalina del acetato de 3-(1h-indol-3-il)-4-[2-(4-metil piperazin-1-il)-quinazolin-4-il]pirrol-2,5-diona; procedimiento de preparacion; y su uso para preparar un medicamento para tratar trastornos mediados por linfocito-t y/o pkc, tales como
FR2903602B1 (fr) Formulation injectable a liberation prolongee de principes actifs, procede pour sa preparation
MX2011012045A (es) Composiciones con liberacion rapida de farmaco.
EA201170843A1 (ru) Предварительно спрессованные быстро распадающиеся лекарственные формы соединений с низкой пероральной биодоступностью
WO2011028062A3 (ko) 신장 증가용 조성물
WO2010104485A3 (en) Valsartan formulations
WO2009004798A1 (ja) 中皮腫の治療剤及び治療方法
GR20100100130A (el) Διεργασια παραγωγης σφαιριδιων παρατεταμενης αποδεσμευσης με την τεχνικη ψεκασμου τηγματος σε διαταξη ρευστης κλινης με ροτορα